SALIX PHARMACEUTICALS LTD

Raleigh, NC · CIK 0001009356 · Biotech · Acquired

Specialty pharmaceutical treatments for gastrointestinal diseases

salix.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$750M
1 Form D · Jan 2014
153 months since last filing
Contracts
—
No federal contracts on record
Patents
40
13 granted · 27 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$750,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2380MANUS BIO INC—$109M
2381Jaguar Health, Inc.—$146M
2382MediWound Ltd.—$31M
2383SALIX PHARMACEUTICALS LTD—$750M
2384Stemsynergy Therapeutic——
2385HiberCell——
2386RaeSedo, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • John ChappellDirector
  • Thomas D'AlonzoDirector
  • Adam DerbyshireExecutive Officer
  • William ForbesExecutive Officer
  • William KeaneDirector
  • Carolyn LoganDirector · Executive Officer
  • Rick ScruggsExecutive Officer
  • Mark SirgoDirector

Patents

USPTO · 13 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.